TTFields plus TMZ treatment effects on newly diagnosed Glioblastoma patients in peripheral blood

We report the application of single-cell-RNA-based sequencing technology for high-throughput profiling of peripheral blood mononuclear cells. By sequencing in total of 193,760 PBMCs in 12 GBM patients, we generated an overview of patient peripheral immune status with 38 biologically recongnized cell subtypes. By paired comparing pre- and post- treatment samples, we find a robust post-TTFields activation of adaptive immunity via the T1IFN trajectory anchored by plasmacytoid DCs. This study provides a framework for the application of scRNAseq towards characterization of peripheral immune activation status. Overall design: Examination of TTFields plus TMZ treatment effects in peripheral blood mononuclear cells. We collected PBMCs from 12 adult patients with newly diagnosed GBM after they have completed radiotherapy with concurrent TMZ. The first time point is at least 2 weeks after completion of chemoradiation and within 2 weeks before initiation of TTFields and TMZ. The second time point is approximately 4 weeks after initiation of TTFields and TMZ.